ACA
VNDA icon

Avoro Capital Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Avoro Capital Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-430,000
Closed -$9.87M – 44
2018
Q3 		$9.87M Sell
430,000
-2,370,191
-85% -$48.4M 0.45% 30
2018
Q2 		$53.3M Buy
2,800,191
+25,000
+0.9% +$418K 2.05% 18
2018
Q1 		$46.8M Buy
2,775,191
+1,366,245
+97% +$22.9M 2.23% 19
2017
Q4 		$21.4M Buy
1,408,946
+420,676
+43% +$6.24M 1.39% 21
2017
Q3 		$17.7M Buy
988,270
+86,124
+10% +$1.44M 1.37% 21
2017
Q2 		$14.7M Buy
902,146
+284,946
+46% +$4.11M 1.86% 16
2017
Q1 		$8.64M Buy
617,200
+235,734
+62% +$3.36M 1.1% 23
2016
Q4 		$6.08M Sell
381,466
-446,227
-54% -$7.17M 1.23% 24
2016
Q3 		$13.8M Buy
827,693
+118,114
+17% +$1.59M 2.42% 15
2016
Q2 		$7.94M Sell
709,579
-145,000
-17% -$1.4M 1.76% 20
2016
Q1 		$7.14M Sell
854,579
-406,230
-32% -$3.33M 2.49% 14
2015
Q4 		$11.7M Sell
1,260,809
-863,784
-41% -$8.62M 4.04% 9
2015
Q3 		$24M Buy
2,124,593
+685,900
+48% +$8.39M 6.23% 3
2015
Q2 		$18.3M Buy
+1,438,693
New +$15.5M 5.03% 8

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Avoro Capital Advisors's VNDA Position: Q4 2018 in Review

Avoro Capital Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2018, closing a stake of 430,000 shares — an estimated $9.87M sold.

Avoro Capital Advisors first reported a position in VNDA in Q2 2015 and held it in 14 quarters. The position peaked at $53.3M in Q2 2018. 186 funds tracked by Wall St. Rank hold VNDA as of Q4 2018.

  • Avoro Capital Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Avoro Capital Advisors sold 430,000 Vanda Pharmaceuticals shares in Q4 2018, an estimated $9.87M.
  • Avoro Capital Advisors first reported a position in Vanda Pharmaceuticals in Q2 2015 and held it in 14 quarters.
  • Avoro Capital Advisors's Vanda Pharmaceuticals position peaked at $53.3M in Q2 2018.
  • 186 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2018.

Based on Avoro Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.